Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extrapyramidal adverse effects associated with sertraline

M T Lambert, C Trutia, F Petty

    Progress in Neuro-Psychopharmacology & Biological Psychiatry
    |September 2, 1998
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Psychiatric education at a veterans affairs medical center.

    Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry·2014
    Same author

    Mentoring psychiatric trainees' first paper for publication.

    Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry·2014
    Same author

    Gene expression profiling in the hippocampus of learned helpless and nonhelpless rats.

    The pharmacogenomics journal·2005
    Same author

    Structure of mania: depressive, irritable, and psychotic clusters with different retrospectively-assessed course patterns of illness in randomized clinical trial participants.

    Journal of affective disorders·2002
    Same author

    Pharmacotherapy for post-traumatic stress disorder: a comprehensive review.

    Expert opinion on pharmacotherapy·2002
    Same author

    Olanzapine treatment for post-traumatic stress disorder: an open-label study.

    International clinical psychopharmacology·2001
    Same journal

    Mapping intrinsic neural timescale alterations in major depressive disorder.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Probiotics in reducing negative symptoms of schizophrenia: A systematic review and meta-analysis.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    The IL10 rs1800872 polymorphism differentially modulates the relationship between plasma IL-10 levels and cognitive function in methamphetamine use disorder.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Inflammatory differences and differential response to minocycline augmentation in young adult patients with first-episode drug-naïve melancholic and non-melancholic major depressive disorder.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Beyond gray matter: unveiling the critical role of white matter in Alzheimer's disease.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Chronic pain and stress: Transdiagnostic meta-analytic evidence of convergent network signature with PTSD.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    See all related articles

    Selective serotonin re-uptake inhibitors (SSRIs) like sertraline may cause extrapyramidal side effects. This case report adds to evidence of sertraline-induced movement disorders, likely via neurotransmitter pathway interactions.

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Psychiatry

    Background:

    • Selective serotonin re-uptake inhibitors (SSRIs) are commonly prescribed antidepressants.
    • Extrapyramidal adverse effects (EPS) have been documented with some SSRIs, notably fluoxetine and paroxetine.

    Observation:

    • Recent literature links sertraline, another SSRI, to treatment-emergent EPS.
    • A review identified 13 published cases of sertraline-induced EPS, often with confounding factors or limited quantitative data.
    • This report details a case of sertraline-associated EPS with quantitative Abnormal Involuntary Movement Scale (AIMS) ratings.

    Findings:

    • The case and literature review suggest sertraline, similar to other SSRIs, can induce significant extrapyramidal side effects.
    • These movement disorders are hypothesized to result from interactions between serotonergic and dopaminergic pathways.

    Related Experiment Videos

    Implications:

    • This finding highlights the potential for sertraline to cause movement disorders.
    • It underscores the clinical relevance of neurotransmitter pathway interactions in antidepressant-induced side effects.
    • Clinicians should be vigilant for EPS when prescribing sertraline.